...
首页> 外文期刊>Journal of Cellular Physiology >PCSK9 and infection: A potentially useful or dangerous association?
【24h】

PCSK9 and infection: A potentially useful or dangerous association?

机译:PCSK9和感染:一个潜在的有用的或危险的协会吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Elevated plasma low‐density lipoprotein‐cholesterol (LDL‐C) concentration is the most important risk factor for atherosclerotic cardiovascular diseases (CVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ubiquitously expressed serine proteinase which plays a key role in cholesterol metabolism, but has been found to be implicated in some other lipid‐independent physiological processes. In this review, the role of PCSK9 was evaluated not only concerning lipid metabolism but also hepatitis C virus (HCV) infection, bacterial infections/sepsis, and septic shock. Collected data from clinical trials revealed that treatment with PCSK9 inhibitors has beneficial effects in lowering LDL‐C via inhibition of LDL‐receptors (LDL‐R), an antiviral effect on HCV infection via down‐regulating the surface expression of LDL‐R and CD81 on hepatic cells, and a positive association with increased inflammatory responses, as well as with septic shock by down‐regulation of hepatocyte LDL‐R. On the other hand, PCSK9 inhibition by therapeutic fully humanized antibodies has positive effects in reducing elevated LDL‐C. However, their safety and tolerability is an important issue which has to be taken into consideration.
机译:升高血浆低密度脂蛋白胆固醇(LDL C)应承担的浓度最重要的危险因素动脉粥样硬化性心血管疾病(心血管病)。Proprotein转化酶枯草杆菌蛋白酶/可馨类型9(PCSK9)是一种无所不在地表达了丝氨酸蛋白酶在胆固醇中发挥着关键作用新陈代谢,但被发现牵涉其中在其他一些独立生理脂质量流程。评价不仅涉及脂质代谢而且丙型肝炎病毒(HCV)感染,细菌感染/脓毒症和脓毒性休克。从临床试验显示,收集数据PCSK9抑制剂治疗有益通过抑制效应降低LDL C应承担的低密度脂蛋白受体(低密度脂蛋白检测R),应承担的丙肝病毒的抗病毒效果感染下通过调节表面低密度脂蛋白检测R的表达,肝细胞的研究,和积极的联系增加了与感染性炎症反应,以及冲击,降低肝细胞调节低密度脂蛋白的R。另一方面,PCSK9抑制治疗完全人源化抗体有积极影响在降低低密度脂蛋白升高所致。和耐受性是一个重要的问题考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号